Independence note: this site is not affiliated with The DRIPBaR. The name is used only to identify the company discussed (see the publisher disclosure in the footer). Figures below are dated; The DRIPBaR’s current official documents control.
Franchise fee
$50,000–$55,000
All-in investment (Item 7)
~$147,000–$415,000 (single unit)
Ongoing take (Item 6)
7% royalty + 2% brand fund (~9% of gross effective)
Open units
106 franchised, 0 corporate (2025 FDD)
Claimed pipeline
"600+ locations in development"
The category leader, moving into metabolic
The DRIPBaR is the largest IV-therapy franchise — 106 operational, all-franchised US units per the 2025 FDD — led by an experienced franchise-sales CEO. Through 2026 it has pushed hard into the metabolic lane: peptide programs and GLP-1 (semaglutide/tirzepatide) weight-loss offerings now feature prominently in its consumer marketing. Its investment range, unlike most wellness franchises, genuinely overlaps an owner-operator budget.
The empty earnings page
The FDD contains no Item 19 financial-performance representation at all. A franchisor is not required to publish one — but its absence means every revenue expectation you hear in the sales process is, by definition, not in the disclosure document. Ask why it is absent, and ask what the franchisor will put in writing.
600+ in development vs. 106 open
The recruiting funnel advertises "600+ locations in development" against 106 open units — a roughly 500-unit gap. Development pipelines are real things, but ask the concrete version: how many of those signed in the last 24 months have opened?
The ongoing take and the record
Approximately 9% of gross ongoing (7% + 2%) on a rented brand. The public record also includes franchisee litigation (including a trade-secret dispute involving a bought-out franchise) and marketplace resale listings; as with any pending or settled matter, verify current status and assume no outcome.
Take these questions to them
“Why does the FDD contain no Item 19 earnings disclosure?”
“How many of the '600+ in development' have opened in the last 24 months?”
“What does ~9% of gross total over ten years at my projected volume?”
“How do the peptide and GLP-1 programs operate if my location's medical oversight lapses?”
Where we stand — disclosedThis site is published by Atlas Metabolic, which offers a 0%-royalty license model in this category (partner owns their own brand; final agreements control). We think the honest comparison — documents, fees, ownership at exit — favors that structure, and you should verify that skepticism-first: see how Atlas structures it, and hold us to the same diligence standard this site applies to everyone else. If you want to see ongoing-fee structures side by side at your own numbers, use the RoyaltyMath calculator.
Sources & dates (retrieved July 29, 2026 unless noted)
The DRIPBaR 2025 FDD digest: franchisepayback.com (units, fees, investment range, absence of Item 19).
ownadripbar.com (development-pipeline and investment marketing claims).